Search

Author/Creator Orkin, C.

1. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study. (August 2018)

Authors:
Vazquez, M.E.; Rockstroh, J.; Lacombe, K.; Orkin, C.; Luetkemeyer, A.; Wyles, D.; Malave, R. Soto; Shermanl, K.E.; Flisiak, R.; Baghani, S.; Shimonova, T.; Slim, J.; Ruane, P.; Sasadeusz, J.
Journal:
International journal of infectious diseases
Issue:
Volume 73(2018)Supplement
Page Start:
372
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. Issue 10 (8th May 2018)

Authors:
Martinello, M.; Bhagani, S.; Gane, E.; Orkin, C.; Cooke, G.; Dore, G. J.; Petoumenos, K.; Applegate, T. L.; Tu, E.; Marks, P.; Pagani, N.; Grebely, J.; Nelson, M.; Matthews, G. V.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 10(2018)
Page Start:
1180
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019)

Authors:
Orkin, C.; Porteiro, N.; Berhe, M.; Dretler, R.; Viciana, P.; Tseng, Y.; Oprea, C.; Johnson, M.; Kulagin, V.; Man, C.; Sievers, J.; Currie, A.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Aboud, M.; Smith, K.; Gartland, M.; Steinhart, C.
Journal:
Journal of infection and public health
Issue:
Volume 12:Issue 1(2019)
Page Start:
147
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗